Roche receives FDA clearance for the cobas® Cdiff Test to detect Clostridium difficile
Roxgold extends QV1 mineralization at Bagassi South and announces additional results from its development infill drilling on the 55 Zone
Roxgold reports financial results for period ended March 31, 2015
Roche Receives FDA Approval for cobas® KRAS Mutation Test
Pivotal Data for Genentech Medicines in Lung and Blood Cancers to Be Presented at ASCO
First movers, including Bristol-Myers, and firms that can aggregate a portfolio of immuno-oncology therapies will be positioned well.
These quality funds with smaller asset bases have portfolios built around solid companies.
As incomes rise, emerging-markets consumers can afford more and better medications driving attractive growth in the pharmaceuticals sector, say the managers of Dodge & Cox International Stock.
Large drugmakers are out of favor, but some good funds are banking on a rebound.